New boxed warnings of clot risk ordered for immune globulin by FDA

06/13/2013 | Medscape (free registration)

The FDA authorized additional warning over the use of human immune globulin products after new data strengthened the connection between such products and thrombosis risk. Drugmakers will have to put additional risk information on the products' current boxed warning labels, while a box warning should be added to the labels of intramuscular and subcutaneous human immune globulin products. Additional data on risk mitigation strategies will also be a requirement.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC